home / stock / cing / cing news

CING News and Press, Cingulate Inc. From 06/29/23

Stock Information
Company Name: Cingulate Inc.
Stock Symbol: CING
Market: NASDAQ
Website: cingulate.com
Menu
CING CING Quote CING Short CING News CING Articles CING Message Board
Get CING Alerts

News, Short Squeeze, Breakout and More Instantly...
CING - Cingulate Successfully Manufactures Clinical Supply - Initiation of Pediatric Phase 3 Studies to Commence in July and August

KANSAS CITY, Kan., June 29, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical ...
CING - Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

KANSAS CITY, Kan., June 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, tod...

CING - Cingulate completes Phase 3 adult study for ADHD drug candidate

2023-06-08 15:27:26 ET Cingulate ( NASDAQ: CING ) said it has completed a Phase 3 study for its drug candidate CTx-1301 in the treatment of ADHD in adults and has slated the initiation of a pivotal Phase 3 pediatric study to begin in Q3. Cingulate expects to receive results ...

CING - Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

Study Assessed Onset and Duration of CTx-1301 in Adults, Results Expected 3Q 2023 Pivotal Phase 3 Trials in Pediatric/Adolescent Patients on Schedule for 3Q 2023 Initiation KANSAS CITY, Kan., June 08, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharma...
CING - Cingulate to Present at 13th Annual LD Micro Invitational

KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, toda...

CING - Cingulate, Indegene to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, toda...

CING - Cingulate GAAP EPS of -$0.35 misses by $0.01

2023-05-10 17:49:49 ET Cingulate press release ( NASDAQ: CING ): Q1 GAAP EPS of -$0.35 misses by $0.01 . Cash Position: As of March 31, 2023, Cingulate had $1.7 million in cash and cash equivalents. For further details see: Cingulate GAAP EPS of -$0.35 misses...
CING - Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 KANSAS CITY, Kan., May 10, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: C...

CING - Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR(TM) Manufacturing Processes to Societal CDMO

KANSAS CITY, Kan., May 03, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutic...

CING - Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Tim...
Previous 10 Next 10